Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer
Source abstract
Abstract
In this study we report the development and optimization of poly (D, L-lactide-co-glycolide) (PLGA) polymer encapsulated poorly aqueous soluble nonsteroidal antiandrogen drug bicalutamide, to develop a sustained release formulation for the treatment of prostate cancer. The bicalutamide-loaded PLGA nanoparticles were prepared by single emulsion (O/W) solvent evaporation method, and different process parameters like polymer concentration in the organic phase, surfactant concentration in aqueous phase and centrifugation speed for separation of nanoparticles were evaluated to optimize the drug-loaded nanoparticles. The optimum formulation of bicalutamide-loaded PLGA nanoparticles characterized extensively by different analytical techniques like laser light scattering to determine average particle size and size distribution, scanning electron microscopy (SEM) for surface morphology, powder X-ray diffraction (PXRD) for surface chemistry and differential scanning calorimetry (DSC) for thermogram properties. Significant decrease of crystallinity of bicalutamide confirms entrapment of the drug within the PLGA polymer matrix. Further, the drug encapsulation efficiency (EE) and in vitro drug release profile were measured by high-performance liquid chromatography and UV-spectrophotometry. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release up to 5 days. Optimum formulation of bicalutamide-loaded PLGA nanoparticles shows significant anti-tumor activity over prostate cancer cell lines (DU 145). The newly developed optimum formulation nanoparticles could be useful for sustained release delivery of bicalutamide.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Quality Assurance, Stadmed Pvt. Ltd., Kolkata, West Bengal, India;
Department of Radiotherapy, Calcutta National Medical College, Kolkata, West Bengal, India;
Quality Assurance Department, Cipla Ltd, Goa, Maharashtra, India
References (52)
Show source-provided references
1. 10.1002/jps.1039710.1002/jps.10397 ↗
2. Aulton ME. 1988. Pharmaceutics: The Science of Dosage Form Design. 4th ed. London, UK: Churchill Livingstone, pp. 69–86.
3. Bolourchian N · Iran J Pharm Res · 2013 · 12 · 11
4. 10.1006/jcis.1995.104710.1006/jcis.1995.1047 ↗
5. 10.1080/0265204050027375310.1080/02652040500273753 ↗
6. 10.1016/0731-7085(93)E0018-I10.1016/0731-7085(93)E0018-I ↗
7. 10.1081/DDC-12002131810.1081/DDC-120021318 ↗
8. Dash S · Acta Pol Pharm · 2010 · 67 · 217
9. 10.1016/j.powtec.2015.04.05310.1016/j.powtec.2015.04.053 ↗
10. 10.4236/jbnb.2012.3202710.4236/jbnb.2012.32027 ↗
11. 10.1211/002235701177519010.1211/0022357011775190 ↗
12. 10.1080/0265204011008139810.1080/02652040110081398 ↗
13. 10.1023/A:102646412441210.1023/A:1026464124412 ↗
14. 10.4155/tde.11.13010.4155/tde.11.130 ↗
15. Hsu HC · Food Drug Anal · 1994 · 2 · 161
16. 10.1016/S0168-3659(01)00248-610.1016/S0168-3659(01)00248-6 ↗
17. 10.1016/0021-9797(75)90134-410.1016/0021-9797(75)90134-4 ↗
18. 10.2174/15734131079165893710.2174/157341310791658937 ↗
19. 10.1016/0378-5173(91)90314-E10.1016/0378-5173(91)90314-E ↗
20. 10.1016/0032-3861(96)81088-310.1016/0032-3861(96)81088-3 ↗
21. 10.1021/la050345110.1021/la0503451 ↗
22. 10.1002/1520-6017(200012)89:12<1558::AID-JPS6>3.0.CO;2-810.1002/1520-6017(200012)89:12<1558::AID-JPS6>3.0.CO;2-8 ↗
23. 10.1016/S0169-409X(00)00103-410.1016/S0169-409X(00)00103-4 ↗
24. 10.1016/S0168-3659(98)00185-010.1016/S0168-3659(98)00185-0 ↗
25. 10.1016/j.ijpharm.2010.11.01510.1016/j.ijpharm.2010.11.015 ↗
26. 10.1016/j.ijpharm.2004.11.02710.1016/j.ijpharm.2004.11.027 ↗
27. Maji R · Int J Nanomed · 2014 · 9 · 3107
28. 10.1074/jbc.M20331020010.1074/jbc.M203310200 ↗
29. McGowen R · Cancer Res · 2000 · 60 · 4771
30. 10.1002/jps.1050710.1002/jps.10507 ↗
31. Müller RH. 1991. Colloidal Carriers for Controlled Drug Delivery and Targeting: Modification, Characterization, and In Vivo Distribution. Stuttgart Boca Raton: Wissenschaftliche Verlagsgesellschaft, CRC Press. pp. 38–44.
32. 10.1016/S0378-5173(99)00187-810.1016/S0378-5173(99)00187-8 ↗
33. 10.1016/S0378-5173(96)04854-510.1016/S0378-5173(96)04854-5 ↗
34. 10.1016/S0169-409X(00)00096-X10.1016/S0169-409X(00)00096-X ↗
35. 10.1002/ijc.2627910.1002/ijc.26279 ↗
36. 10.1007/s11095-005-9046-210.1007/s11095-005-9046-2 ↗
37. Saeedi M · Iran J Pharm Res · 2011 · 10 · 25
38. Sahana B · Int J Nanomed · 2010 · 5 · 621
39. 10.1016/S0168-3659(02)00127-X10.1016/S0168-3659(02)00127-X ↗
40. Sancheti PP · Pharmazie · 2008 · 63 · 571
41. 10.1016/j.ijpharm.2013.02.04210.1016/j.ijpharm.2013.02.042 ↗
42. 10.1007/BF0120911910.1007/BF01209119 ↗
43. 10.1023/A:101198242841310.1023/A:1011982428413 ↗
44. Sun BS · Int J Clin Exp Med · 2015 · 8 · 19670
45. 10.1016/j.ejpb.2008.09.02310.1016/j.ejpb.2008.09.023 ↗
46. Swamivelmanickam M · Int J ChemTech Res · 2009 · 4 · 1189
47. 10.1007/BFb004306210.1007/BFb0043062 ↗
48. 10.1016/j.drudis.2007.09.00510.1016/j.drudis.2007.09.005 ↗
49. 10.1016/0378-5173(95)04243-110.1016/0378-5173(95)04243-1 ↗
50. 10.1016/j.jsps.2015.02.02110.1016/j.jsps.2015.02.021 ↗
51. 10.1016/j.jconrel.2014.06.03810.1016/j.jconrel.2014.06.038 ↗
52. 10.1016/S0142-9612(00)00178-210.1016/S0142-9612(00)00178-2 ↗